BioCryst PharmaceuticalsBCRX +0.40%64 Days Payable is 227.27 as of Mar. 2026, which is 80% below its 10-year median of 1,152.11. GuruFocus rates BCRX with a GF Score™ of 64/100 and a GF Value™ of $12.75 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks better than 82.77% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioCryst Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (BCRX) has a Days Payable of 227.27 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCryst Pharmaceuticals and its competitors. This is 80% below median its historical median of 1,152.11. Over the past decade, BioCryst Pharmaceuticals' Days Payable has ranged from 187.20 to 5,465.70. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #159 out of 923 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is BioCryst Pharmaceuticals' Days Payable too high?
BioCryst Pharmaceuticals' current Days Payable of 227.27 is 80% below median its 10-year median of 1,152.11. Over the past 10 years, this metric has ranged from a low of 187.20 to a high of 5,465.70. The Drug Manufacturers industry median Days Payable is 90.98. BioCryst Pharmaceuticals' value of 227.27 is 149.8% above this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #159 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Days Payable compare to PBH and SUPN?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #159 out of 923 companies for Days Payable. This places BioCryst Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. BioCryst Pharmaceuticals' value of 227.27 is 149.8% above this benchmark. Historically, BioCryst Pharmaceuticals' own Days Payable has ranged from 187.20 to 5,465.70 over the past decade. While the company's 10-year median is 1,152.11 vs. the industry median of 90.98, BioCryst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current Days Payable of 227.27 is 149.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current Days Payable is 227.27, which is 80% below median its own 10-year median of 1,152.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.75, compared to a current price of $9.97 — trading 21.8% below its estimated fair value. The current Days Payable is 227.27, which is 80% below median its 10-year median of 1,152.11 and 149.8% above the Drug Manufacturers industry median of 90.98. BioCryst Pharmaceuticals' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Days Payable is 227.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.97 is trading 21.8% below its estimated GF Value™ of $12.75.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
Days Payable: 227.27 (80% below median its 10-year median of 1,152.11)
GF Value™: $12.75 vs. price of $9.97 (21.8% below fair value)
Industry Position: 149.8% above the Drug Manufacturers median (#159 of 923)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
64GF Score
Get the complete analysis for BCRX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
